about
Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease.Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML).Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.Pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, combined with azacitidine, in patients with AML.A multi-center Phase 1 trial of ipilimumab in myelodysplastic syndrome patients following hypomethylating agent failure.Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapyDiagnosis and management of viral myocarditisThe tissue's the issuePainless jaundiceLenalidomide-associated hemolytic anemiaOptimizing the management of relapsed chronic myeloid leukemia post-allogeneic bone marrow transplantClonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatmentConjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacyCyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approachVenetoclax-induced tumour lysis syndrome in acute myeloid leukaemiaFinal results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)Trials and Tribulations of Corrected QT Interval Monitoring in Oncology: Rationale for a Practice-Changing Standardized ApproachInversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET)Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDSDifferentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML
P50
Q34055591-87183DA6-4450-487B-A294-1E5ADE0B13D9Q34714792-035219FE-C800-4964-8341-3E7ED102ED57Q37245754-4B59208C-6537-4E1B-B7E4-624BDE373C5CQ38367533-80FDB8EE-12F1-40BC-8893-36466BC0EDC3Q38621659-26F53E01-8253-473E-BF72-B514B1E7FB30Q48216923-5789D487-4F77-4A92-93BD-944B2E0532F3Q52714959-5C2520F4-9863-482C-A9F6-B2C9EEB80FABQ58617289-CBC97605-CA79-4F69-AD51-D5221E8A14B1Q80552340-A74FBA1C-644D-4EE4-931A-A89C592723E9Q84072690-5A7437FC-E74B-4BCC-9FD9-5D3BA3D5A3F1Q84539211-386B0059-954B-458E-80E0-90175760E384Q86644982-D5B4C8FE-987B-4695-A0B1-89F228E2734BQ86985024-80DA2505-1721-4017-A9DB-E45E71A1B339Q88637766-B16E8E2F-4A31-4E9C-8B16-CA06654DEB33Q90253675-C6B6A0F9-A993-4AF1-AD1C-4F257AC9FCDAQ90710456-3DC52082-129A-4783-BEC8-D94297765D68Q90762942-5BAABA13-4FE4-4FFF-9EC7-1F7980737212Q91005451-D2F41227-28B6-41F8-A224-40D1ABC2E3D3Q91922986-F73F546D-4CE5-4DDA-B92E-C89D5C38DBA3Q92235343-0FEAC523-D8B7-492D-A8CB-48AAACE759ECQ92407035-80BA267B-65C6-4BB5-A91F-BDD95C0B3479Q96589958-47C6BD3C-9A59-4F79-8C5B-F532E69C1E71
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Joshua Zeidner
@en
Joshua Zeidner
@nl
type
label
Joshua Zeidner
@en
Joshua Zeidner
@nl
prefLabel
Joshua Zeidner
@en
Joshua Zeidner
@nl
P31
P496
0000-0002-9014-1514